title: [From risk factors to symptomatic coronary artery disease. Update cardiology 2001/2002--part I].
abstract: The cardiovascular continuum describes the way from risk factors to atherosclerosis, acute cardiovascular events (unstable angina and myocardial infarction), and development of terminal heart failure and its complications. Following this way, advances are reported in the prevention of cardiovascular disease, in noninvasive diagnostics and revascularization of coronary artery disease, and in new therapeutic options of acute myocardial infarction. The following issues are reported in detail: (1) significance of statins, inhibition of platelet aggregation and vitamins in primary and secondary prevention of cardiovascular disease, (2) comparison of the angiotensin receptor blocker losartan and the beta-blocker atenolol in hypertension (LIFE study), (3) magnetic resonance angiography for the detection of coronary stenoses, (4) advantages and disadvantages of operative and interventional coronary revascularization considering elderly patients and sirolimus-eluting stents, and (5) efficacy of glycoprotein IIb/IIIa inhibition and low molecular weight heparin in acute myocardial infarction.
authors.affiliation: Medizinische Klinik und Poliklinik, Innere Medizin III, Kardiologie/Angiologie, Universitätskliniken des Saarlandes, Hamburg/Saar. fries@med-in.uni-saarland.de
authors.forename: Roland
authors.initials: R
authors.lastname: Fries
authors.forename: Michael
authors.initials: M
authors.lastname: Böhm
mesh_terms: D000077284:Abciximab; D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000789:Angina, Unstable / Q000175:diagnosis / Q000517:prevention & control / Q000601:surgery; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001262:Atenolol / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000401:mortality / Q000517:prevention & control*; D002986:Clinical Trials as Topic; D017023:Coronary Angiography; D001026:Coronary Artery Bypass; D003327:Coronary Disease / Q000175:diagnosis / Q000000981:diagnostic imaging / Q000601:surgery; D023903:Coronary Restenosis / Q000517:prevention & control; D023921:Coronary Stenosis / Q000175:diagnosis / Q000517:prevention & control; D005260:Female; D005500:Follow-Up Studies; D006333:Heart Failure / Q000188:drug therapy / Q000517:prevention & control; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D007140:Immunoglobulin Fab Fragments / Q000008:administration & dosage / Q000627:therapeutic use; D019808:Losartan / Q000627:therapeutic use; D018810:Magnetic Resonance Angiography; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D009203:Myocardial Infarction / Q000175:diagnosis / Q000188:drug therapy / Q000517:prevention & control; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors; D011322:Primary Prevention; D012307:Risk Factors; D012737:Sex Factors; D015607:Stents; D015912:Thrombolytic Therapy; D013997:Time Factors; D014815:Vitamins / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D000959:Antihypertensive Agents; D006495:Heparin, Low-Molecular-Weight; D000960:Hypolipidemic Agents; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D014815:Vitamins; D001262:Atenolol; D019808:Losartan; D000077284:Abciximab
vernacular_title: Kardiologie 2001/2002--Teil I. Vom Risikofaktor zur symptomatischen koronaren Herzkrankheit.